Investigational Drug Details
| Drug ID: | D223 |
| Drug Name: | Metabolic Cofactor Supplementation |
| Synonyms: | combined metabolic activators; CMA |
| Type: | Supplement |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | Yes |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 on-going (NCT04330326: CMA can be used to develop a pharmacological treatment strategy in NAFLD patients.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0018 | NCT04330326 | Phase 2 | Unknown status | No Results Available | July 20, 2019 | April 1, 2020 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|